伊马替尼和布利纳单抗成功拯救了一名对达沙替尼和化疗耐药的TERF2::PDGFRB融合的儿童B-ALL患者。

IF 2.4 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-09-20 DOI:10.1007/s00277-025-06620-7

Fanghua Ye, Leyuan Wang, Yujie Qian, Wenjun Deng, Yan Yu, Liangchun Yang

{"title":"伊马替尼和布利纳单抗成功拯救了一名对达沙替尼和化疗耐药的TERF2::PDGFRB融合的儿童B-ALL患者。","authors":"Fanghua Ye, Leyuan Wang, Yujie Qian, Wenjun Deng, Yan Yu, Liangchun Yang","doi":"10.1007/s00277-025-06620-7","DOIUrl":null,"url":null,"abstract":"PDGFRB-rearranged acute lymphoblastic leukemia (ALL), an ABL-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a TERF2::PDGFRB fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among PDGFRB-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for PDGFRB-rearranged ALL.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.\",\"authors\":\"Fanghua Ye, Leyuan Wang, Yujie Qian, Wenjun Deng, Yan Yu, Liangchun Yang\",\"doi\":\"10.1007/s00277-025-06620-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PDGFRB-rearranged acute lymphoblastic leukemia (ALL), an ABL-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a TERF2::PDGFRB fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among PDGFRB-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for PDGFRB-rearranged ALL.\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00277-025-06620-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06620-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

pdgfrb重排急性淋巴细胞白血病（ALL）是一种abl类ph样ALL亚型，典型表现为化疗耐药和预后差。精确的诊断和治疗对于改善预后至关重要。在这里，我们报告了一例9岁男性携带TERF2::PDGFRB融合，表现出对达沙替尼的原发性耐药，但对伊马替尼取得了显着的反应。随后与blinatumumab联合治疗诱导持续骨髓缓解。这些发现强调了pdgfrb重排ALL病例中酪氨酸激酶抑制剂（TKIs）敏感性的可变性，支持在反应不佳时早期切换治疗。值得注意的是，blinatumomab和伊马替尼联合使用可能是pdgfrb重排ALL的有效治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.

PDGFRB-rearranged acute lymphoblastic leukemia (ALL), an ABL-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a TERF2::PDGFRB fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among PDGFRB-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for PDGFRB-rearranged ALL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.